#ChRCC
Complementary Diagnostic Value of ZEB1 and CK7 in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma www.ovid.com/10.1097/PAI....
Complementary Diagnostic Value of ZEB1 and CK7 in... : Applied Immunohistochemistry & Molecular Morphology
Renal oncocytoma (RO) is a benign renal epithelial tumor that may closely mimic chromophobe renal cell carcinoma (chRCC), particularly in limited...
www.ovid.com
October 14, 2026 at 12:35 AM
I had no idea there was such a thing as World Kidney Day.

Even more ironic is learning about this while having ChRCC kidney cancer and less than a week away from having a partial/full nephrectomy. 😳 The universe sure does send some strange signals at times.
npr.org NPR @npr.org · Mar 13
For World Kidney Day, we look back at this story on the more than 90,000 people in the U.S. who are waiting for a kidney transplant. A kidney shortage means many die on the waitlist or become too sick for a transplant. A new plan would compensate donors.
There's a severe kidney shortage. Should donors be compensated?
More than 90,000 people in the U.S. are waiting for a kidney transplant. But a kidney shortage means many die on the waitlist or become too sick for a transplant. A new plan would compensate donors.
www.npr.org
March 14, 2025 at 3:30 AM
Chromophobe renal cell carcinoma (ChRCC), kidney, H&Es, 20x and 40x, CK7, 20x: Plant-like tumor cells - Vimentin negative; CK7 and C-Kit positive!
#pathology #pathsky #surgicalpathology #renalpathology #renalcellcarcinoma #renalpathology #RCC #kidneypathology #ChRCC #pathart
November 18, 2024 at 10:35 PM
Feed: "Oncodaily | Oncology News, Insights, Stories"
Published on Friday, July 25, 2025
Katie Coleman: Coffee with Chromies Is Back
Katie Coleman: Coffee with Chromies Is Back / cancer, chRCC, Chromophobe and Oncocytic Tumor Alliance, Katie Coleman, KCCure, kidney cancer, Kidney Cancer
oncodaily.com
July 26, 2025 at 6:19 AM
Feed: "Medical Xpress - latest medical and health news stories"
Published on Thursday, July 3, 2025
Rare kidney cancer resists immune therapies due to lack of active T-cells
Cancer-fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the t...
medicalxpress.com
July 3, 2025 at 7:27 PM
Chromophobe renal cell carcinoma contains few active T-cells and responds poorly to immune therapies, highlighting the need for new treatment strategies targeting its unique immune environment. doi.org/g9r9wc
Rare kidney cancer resists immune therapies due to lack of active T-cells
Cancer-fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the tumor threat and traditional immune therapies, revealing the need for new targets and treatments.
medicalxpress.com
July 4, 2025 at 4:32 AM
Breakthrough Discoveries in Chromophobe Renal Cell Carcinoma Biology Open Doors to New Therapeutic Approaches

New Haven, Conn. — In an extensive new investigation into the biology of kidney cancers, researchers have uncovered critical insights that may reshape therapeutic approaches to a rare but…
Breakthrough Discoveries in Chromophobe Renal Cell Carcinoma Biology Open Doors to New Therapeutic Approaches
New Haven, Conn. — In an extensive new investigation into the biology of kidney cancers, researchers have uncovered critical insights that may reshape therapeutic approaches to a rare but challenging subtype known as chromophobe renal cell carcinoma (ChRCC). Unlike other kidney cancers, ChRCC exhibits a stark deficiency in cancer-fighting T-cells, the immune system’s frontline agents responsible for identifying and destroying malignant cells.
scienmag.com
July 3, 2025 at 5:18 PM
Huge credit to André Figueiredo (PhD, Biochem
@laqv-requimte.bsky.social). Collaboration with @UPMC
fueling clinical impact.

📎 Full story: doi.org/10.1016/j.ta...
#Proteomics #ccRCC #pRCC #chRCC #Oncocytoma #CancerDiagnostics #PROTEOMICSNOVA
July 12, 2025 at 10:50 AM
Progress for chromophobe RCC at ASCO GU. Excited to check out the FOUR abstracts for #chRCC tomorrow (H31, H18, E21, E36) #chromophobe #GU25
@msaouel.bsky.social
February 15, 2025 at 4:49 AM
Long-term data show higher-stage chRCC patients have worse outcomes than those with lower-stage chRCC, oncocytoma, or ORNLMP, according to research presented at #IKCSNA25. shorturl.at/c54by
November 14, 2025 at 4:12 PM
A rare #kidneycancer, chromophobe RCC, resists traditional immunotherapy because of its ability to hide from the immune system. A @yalecancer.bsky.social-led study in the Journal of Clinical Oncology reveals the tumor’s unique biology.
www.yalecancercenter.org/news-article...
@braunmdphd.bsky.social
Novel insights into chromophobe renal cell carcinoma biology and potential therapeutic strategies
Cancer fighting T-cells, the immune system’s primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those
www.yalecancercenter.org
July 2, 2025 at 8:34 PM